Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown. METHODS: We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI). RESULTS: Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups. CONCLUSIONS: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although effective, ERT is limited by an approximately 40% noncompliance rate, costs ≥$200,000 annually, and advances arthropathy.172, 173, 174, 175”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [172]
Citations
Cites
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
A Radiologic Classification of Hemophilic Arthropathy
PETTERSSON, H., AHLBERG, Å., & NILSSON, I. M. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198006000-00018 · Cited by 549
Proceedings: A more uniform measurement of factor VIII inhibitors.
Ck, K., Aledort, L. M., Aronson, D. D., Counts, R., Edson, van Eys, J., Fratantoni, J. C., Green, D., Hampton, J., Hilgartner, M. W., et al. (1975) · PubMed · Cited by 346
Barriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationAhlberg, Å. (1965) · Acta Orthopaedica Scandinavica · doi:10.3109/ort.1965.36.suppl-77.01 · Cited by 252
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
Soucie, J. M. (2004) · Blood · doi:10.1182/blood-2003-05-1457 · Cited by 244
Self-citationIorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
Nuss, R., Kilcoyne, R. F., Geraghty, S., Shroyer, A. L. W., Rosky, J. W., Mawhinney, S., Wiedel, J., & Manco‐Johnson, M. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00383.x · Cited by 159
Self-citationLee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., Kreuz, W., Escuriola‐Ettingshausen, C., Funk, M. J., SCHMIDT, H., & Kornhuber, B. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440413.x · Cited by 154
Research works printed but not linked: 5
- Robinson PM, 1967, Can Med Assoc J, 97, 559
- Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #193. New York: National Hemophilia Foundation, March 11, 1994.
- Stobart K, 2006, Cochrane Database Syst Rev, 2, CD003429
- Kasper CK, 1975, Thromb Diath Haemorr, 34, 612
- Report on the Universal Data Collection Program. Atlanta: Centers for Disease Control and Prevention, 2005;7(1):28. (Accessed July 18, 2007, athttp://www.cdc.gov/ncbddd/hbd/documents/UDC7%281%29.pdf.)
Cited by
Items 701–800 of 1,000
Liou, W., Tu, T., CHENG, S. ‐., Chou, T.-Y., Lee, C., LIN, T. ‐., Chung, M., & Cham, T. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02367.x · Cited by 19
Mondorf, W., Kalnins, W., & Klamroth, R. (2013) · Haemophilia · doi:10.1111/hae.12136 · Cited by 19
Hemophilic Arthropathy of the Elbow
Adams, J. E., & Reding, M. T. (2011) · Hand Clinics · doi:10.1016/j.hcl.2011.01.007 · Cited by 19
Pipe, S. W. (2009) · Biologics · doi:10.2147/btt.2009.2872 · Cited by 19
“It has proven effi cacious in preventing bleeds and joint disease.(2) This also correlates with a reduction in hospital admissions, emergency department and clinic visits,(14) and improved academic performance and accomplishments.”
Ragni, M. V., & Malec, L. M. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.963550 · Cited by 19
“Furthermore, several groups have shown that blocking T-cell response in mouse models before injection of FVIII via FVIII-primed immature dendritic cells, which are CD4+CD25+ professional antigen-presenting cells, significantly reduces inhibitor response [23,24], and is accompanied by an increase IL-10 production by sp…”
BackgroundInfluentialLong-lasting recombinant factor VIII proteins for hemophilia A
Shapiro, A. D. (2013) · Hematology · doi:10.1182/asheducation-2013.1.37 · Cited by 21
Self-citationMcMullen, S., Buckley, B. C., Hall, E., Kendter, J., & Johnston, K. (2016) · Value in Health · doi:10.1016/j.jval.2016.09.2396 · Cited by 19
Ettingshausen, C. E., Hegemann, I., Simpson, M. L., Cuker, A. C., Kulkarni, R., Pruthi, R. K., Garly, M., Meldgaard, R. M., Persson, P., & Klamroth, R. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12192 · Cited by 19
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study
Oldenburg, J., Shima, M., Kruse‐Jarres, R., Santagostino, E., Mahlangu, J. N., Lehle, M., Bienz, N. S., Chebon, S., Asikanius, E., Trask, P. C., et al. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28474 · Cited by 19
Måseide, R. J., Berntorp, E. E., Astermark, J., Hansen, J., Olsson, A., Bruzelius, M., Frisk, T., Aspdahl, M., Nummi, V., Tjønnfjord, G. E., et al. (2021) · Haemophilia · doi:10.1111/hae.14245 · Cited by 19
Klamroth, R., Wojciechowski, P., Aballéa, S., Diamand, F., Hakimi, Z., Nazir, J., Abad‐Franch, L., Lethagen, S., Santagostino, E., & Tarantino, M. D. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s288283 · Cited by 19
Li, N., Sawyer, E. K., Maruszczyk, K., Guzauskas, G. F., Slomka, M. T., Burke, T., Martin, A. P., O’Hara, J., Stevenson, M., & Recht, M. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1891088 · Cited by 21
“The severity of HB is defined by the level of circulating FIX and management is based on FIX replacement therapy administered either prophylactically to prevent bleeding episodes or after a bleeding episode has occurred, known as “ on-demand ” treatment 5,6 .”
BackgroundInfluentialSelf-citationHOWMAN, R., Barnes, C., Curtin, J. A., Price, J., Robertson, J. D., Russell, S., Seldon, M., Suppiah, R., Teague, L. R., & Barrese, G. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02445.x · Cited by 19
Revisiting hemophilia management in acute medicine
Sahu, S., Lata, I., Singh, S. M., & Kumar, M. (2011) · Journal of Emergencies Trauma and Shock · doi:10.4103/0974-2700.82225 · Cited by 19
“[23] In one recent approach, the recombinant factor VIII molecule is noncovalently attached to a pegylated liposome molecule prior to infusion.”
Shapiro, A. D., & Hedner, U. K. E. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611415566 · Cited by 19
Self-citationCastaman, G., & Linari, S. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s87543 · Cited by 19
“Primary prophylaxis is the regular continuous treatment initiated in the absence of documented osteochondral joint disease and started before the second clinically evident large joint bleeding and the age of 3 years(44) and currently represents the primary goal of FVIII replacement therapy.(45) Primary prophylaxis is…”
Cuesta‐Barriuso, R., Torres‐Ortuño, A., Galindo‐Piñana, P., Nieto‐Munuera, J., Duncan, N., & Pina, J. A. L. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s126828 · Cited by 19
“4,5 It has been proven to be effective in decreasing both the number of visits to emergency services and hospitalizations, increasing physical activity as well as improving absenteeism and school performance.”
Zhao, Y., Xiao, J., Yang, R., Wu, R., Hu, Y., Beckmann, H., Wu, J., Hou, Q., & Sun, J. (2017) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2017.1313921 · Cited by 19
“The current results confirm the previously reported benefits of prophylaxis in children, both in China [15,16] and elsewhere [2,3].”
BackgroundResultInfluentialAdvances in Hemophilia: Experimental Aspects and Therapy
Rodriguez, N. I., & Hoots, W. K. (2008) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2008.01.010 · Cited by 19
Self-citationKarapınar, T. H., Karadaş, N., Özek, G., Tüfekçi, Ö., Atabay, B., Türker, M., Yüksel, F., Karapınar, D. Y., Vergin, C. R., İrken, G., et al. (2014) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000131 · Cited by 19
Coppola, A., D’Ausilio, A., Aiello, A., Amoresano, S., Toumi, M., Mathew, P., Tagliaferri, A., & the Potter Study Group (2017) · Haemophilia · doi:10.1111/hae.13185 · Cited by 18
Self-citationClinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
Quellec, S. L. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s167731 · Cited by 18
“Altogether, emicizumab represents an interesting therapeutic approach in HA pediatric patients with or without FVIII-inhibitors because it has been shown that the lower the bleeding rate, the lower the long-term complications of hemophilia such as hemophilic arthropathy.(1,2) We can expect that if hemophilic arthropat…”
BackgroundHaemophilia and Fragility Fractures: From Pathogenesis to Multidisciplinary Approach
Alito, A., Bellone, F., Portaro, S., Leonardi, G., Cannavò, V., Coppini, F., Leonetti, D., Catalano, A., Squadrito, G., & Fenga, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119395 · Cited by 20
“Bleeding occurs in the major synovial joints, such as the ankles, knees and elbows, and its repetitive nature is widely recognized as key to the development of haemophilic arthropathy [22].”
BackgroundClinical pharmacology of emicizumab for the treatment of hemophilia A
Yoneyama, K., Schmitt, C., Portron, A., Kiialainen, A., Kotani, N., Jaminion, F., Retout, S., & Adamkewicz, J. I. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2243213 · Cited by 24
“demonstrated, making prophylaxis a standard treatment for PwHA [2,8].”
BackgroundFischer, K., Lassila, R., Peyvandi, F., Gatt, A., Hollingsworth, R., Lambert, T., Kaczmarek, R., Bettle, A., Samji, N., Rivard, G., et al. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102265 · Cited by 23
“Consequently, patients are able to live a normal and productive life, albeit needing frequent i.v. infusions [1 – 3].”
BackgroundBerntorp, E. E., Fischer, K., & Miners, A. H. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02839.x · Cited by 18
Ullman, M. M., Zhang, Q. C., Brown, D., Grant, A., & Soucie, J. M. (2013) · Haemophilia · doi:10.1111/hae.12303 · Cited by 20
Self-citationTwo global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A
Antović, J. P., Miković, D., Elezović, I. V., Holmström, M., Wilkens, M., Elfvinge, P., Soutari, N. M. H., & Antovič, A. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0811 · Cited by 18
Lochan, A., Macaulay, S., Chen, W. C., Mahlangu, J. N., & Krause, A. (2014) · Haemophilia · doi:10.1111/hae.12436 · Cited by 18
Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan
Taki, M., Shirahata, A., & THERAPY, F. T. F. S. O. R. R. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01823.x · Cited by 18
Haemophilic synovitis of the elbow: Radiosynovectomy, open synovectomy or arthroscopic synovectomy?
Rodriguez-Merchan, E. C. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.05.025 · Cited by 18
“Routine prophylaxis is an important treatment strategy for patients with severe hemophilia [1–3].”
BackgroundProphylaxis in bleeding disorders
Oldenburg, J. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.10.005 · Cited by 18
Hemophilic synovitis of the knee: radiosynovectomy or arthroscopic synovectomy?
Rodriguez-Merchan, E. C. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.926809 · Cited by 18
MALDI Imaging of predictive ferritin, fibrinogen and proteases in haemophilic arthropathy
Kriegsmann, M., Casadonte, R., Randau, T. M., Gravius, S., Pennekamp, P. H., Strauss, A. C., Oldenburg, J., Wieczorek, K. S., Deininger, S., Otto, M., et al. (2014) · Haemophilia · doi:10.1111/hae.12377 · Cited by 18
An innovative outcome-based care and procurement model of hemophilia management
Gringeri, A., Doralt, J., Valentino, L. A., Crea, R., & Reininger, A. J. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2016.1178066 · Cited by 18
Self-citationA new toolkit for conducting clinical trials in rare disorders.
Abrahamyan, L., Diamond, I. R., Johnson, S. R., & Feldman, B. M. (2014) · PubMed · Cited by 18
Nogami, K., Taki, M., Matsushita, T., Ohga, S., Oka, T., Horikoshi, Y., Amano, K., & Shima, M. (2018) · Haemophilia · doi:10.1111/hae.13531 · Cited by 18
TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding
Wyseure, T. L., Yang, T., Zhou, J. Y., Cooke, E. J., Wanko, B., Olmer, M., Agashe, R., Morodomi, Y., Behrendt, N., Lotz, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128379 · Cited by 18
“Today’s focus on managing acute bleeds in hemophilia and optimizing prophylactic treatment has significantly reduced the number of life-threatening bleeds and delayed the early onset of HA (1).”
BackgroundBispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
Shima, M. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12337 · Cited by 18
Zhao, H., Yang, L., Long, C., Guo, Y., Wu, R., Liu, X., Qin, X., Liang, H., & Duan, Z. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1043263 · Cited by 18
“Evidence suggests that prophylactic therapy can prevent initial joint damage and decrease the frequency of joint hemorrhages in PWH, and that hospitalization rates are approximately 50% lower than those of patients who receive on-demand treatment [13,14].”
BackgroundPrevention of arthropathy in haemophilia: prophylaxis
Santagostino, E., & Mancuso, M. E. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01884.x · Cited by 18
Rodriguez-Merchan, E. C., Hedner, U. K. E., Heijnen, L., Jiménez‐Yuste, V., Lee, C. A., Morfini, M., Querol, F., Roosendaal, G., Santagostino, E., & Solimeno, L. P. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01892.x · Cited by 18
Galli, E., Baques, A. C., Moretti, N., Candela, M., & Caviglia, H. A. (2012) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-012-0480-3 · Cited by 18
Optimising musculoskeletal care for patients with haemophilia
Carcao, M. D., Hilliard, P., Escobar, M. A., Solimeno, L. P., Mahlangu, J. N., & Santagostino, E. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12581 · Cited by 18
“In certain cases, joint damage may develop despite no clinically-evident episodes of joint bleeding, which has been attributed to the presence of unrecognised subclinical haemarthroses (11).”
BackgroundFocusing in on use of pharmacokinetic profiles in routine hemophilia care
Croteau, S. E., Callaghan, M. U., Davis, J. A., Dunn, A. L., Guerrera, M. F., Khan, O. A., Neufeld, E. J., Raffini, L. J., Recht, M., Wang, M., et al. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12118 · Cited by 17
Self-citationMinno, A. D., Spadarella, G., Nardone, A., Mormile, M., Ventre, I., Morfini, M., & Minno, G. D. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.08.003 · Cited by 21
Comprehensive care for hemophilia and other inherited bleeding disorders
Page, D. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2019.08.005 · Cited by 18
Zhang, F., Xu, M., Yang, Q. Z., Hua, B., Xia, B., Lin, Z.-Y., Xiao, X., Monahan, P. E., & Sun, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010075 · Cited by 18
“As current prophylactic regimens do not completely prevent joint bleeding, some patients may still develop joint disease [3,4].”
BackgroundHemophilia without prophylaxis: Assessment of joint range of motion and factor activity
Wang, M., Recht, M., Iyer, N. N., Cooper, D. L., & Soucie, J. M. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12347 · Cited by 19
Self-citationOlasupo, O. O., Lowe, M. S., Krishan, A., Collins, P. W., Iorio, A., & Matino, D. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014201 · Cited by 17
Astermark, J., Blatný, J., Königs, C., Hermans, C. R. J. R., Jiménez‐Yuste, V., & Hart, D. P. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231165857 · Cited by 18
Franchini, M., Makris, M., Santagostino, E., Coppola, A., & Mannucci, P. M. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2011.02745.x · Cited by 17
Ingerslev, J., Lethagen, S., Poulsen, L. H., Sørensen, B., Lopatina, E., Tentsova, I. A., Yastrubinetskaya, O., & Plyushch, O. P. (2013) · Haemophilia · doi:10.1111/hae.12242 · Cited by 17
Opinions on radiosynovectomy for chronic haemophilic synovitis: point/counterpoint
Silva, M., Luck, J. V., & Leissinger, C. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02908.x · Cited by 17
Self-citationHemofilia: ejercicio y deporte
Querol, F., Pérez‐Alenda, S., Gallach, J. E., Devís‐Devís, J., Valencia‐Peris, A., & González, L.-M. (2011) · Apunts Sports Medicine · doi:10.1016/j.apunts.2010.09.002 · Cited by 17
Aznar, J. A., García‐Dasí, M., Pérez‐Alenda, S., Marco, A., Jaca, M., Moret, A., & Querol, F. (2013) · Vox Sanguinis · doi:10.1111/vox.12066 · Cited by 17
Hemophilia clinical gene therapy: brief review
Walsh, C., & Batt, K. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.016 · Cited by 22
Teitel, J. M., & Sholzberg, M. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.02.003 · Cited by 17
Windyga, J., Trujillo, M. H. S., & Hafeman, A. E. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714550573 · Cited by 17
Future of haemophilia outcome assessment: registries are key to optimized treatment
Berntorp, E. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12504 · Cited by 17
Mason, J. A., Parikh, S., Tran, H. A., Rowell, J., & McRae, S. J. (2018) · Haemophilia · doi:10.1111/hae.13375 · Cited by 17
Tolerance induction in hemophilia: innovation and accomplishments
Sherman, A., Biswas, M., & Herzog, R. W. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000446 · Cited by 17
Elnaggar, R. K. (2019) · Lasers in Medical Science · doi:10.1007/s10103-019-02889-z · Cited by 17
McEneny‐King, A., Yeung, C. H. T., Edginton, A. N., Iorio, A., & Croteau, S. E. (2019) · Haemophilia · doi:10.1111/hae.13882 · Cited by 17
Pérez‐Llanes, R., Meroño‐Gallut, J., Donoso‐Úbeda, E., Pina, J. A. L., & Cuesta‐Barriuso, R. (2020) · Physiotherapy Theory and Practice · doi:10.1080/09593985.2020.1744207 · Cited by 18
“The gold standard in the treatment of hemophilia is the prophylactic administration of the missing clotting factor (Manco-Johnson et al., 2007).”
BackgroundMinno, M. N. D. D., Minno, A. D., Calcaterra, I. L., Cimino, E., Dell’Aquila, F., & Franchini, M. (2020) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0040-1718887 · Cited by 20
Park, Y. S., Hwang, T. J., Cho, G.-J., Kim, S. K., Park, S. K., Kim, J. Y., Baek, H. J., Kim, Y., Lee, H., Shin, J., et al. (2021) · Haemophilia · doi:10.1111/hae.14304 · Cited by 17
Tagliaferri, A., Molinari, A. C., Peyvandi, F., Coppola, A., Demartis, F., Biasoli, C., Borchiellini, A., Cultrera, D., CRISTOFARO, R. D., Daniele, F., et al. (2022) · Haemophilia · doi:10.1111/hae.14689 · Cited by 18
Estimating unknown parameters in haemophilia using expert judgement elicitation
Fischer, K., Lewandowski, D., & Janssen, M. P. (2013) · Haemophilia · doi:10.1111/hae.12166 · Cited by 22
Yao, W., Xiao, J., Cheng, X., Feng, G., Li, C., Zhang, X., Hu, Q., Xu, W., Sun, J., Yang, R., et al. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616679507 · Cited by 17
Osooli, M., Carlsson, K. S., Baghaei, F., Holmström, M., Rauchensteiner, S., Holme, P. A., Poulsen, L. H., Astermark, J., & Berntorp, E. E. (2017) · Haemophilia · doi:10.1111/hae.13231 · Cited by 17
Muscle function deterioration in patients with haemophilia: Prospective experience from Costa Rica
Seuser, A., Navarrete‐Duran, M., Auerswald, G., & Mancuso, M. E. (2018) · Haemophilia · doi:10.1111/hae.13455 · Cited by 17
Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics
Zhou, J. Y., Barnes, R. F. W., Foster, G., Iorio, A., Cramer, T. J., & von Drygalski, A. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619862052 · Cited by 19
“During periods of 15 days preceding bleeds, we found that: (1) factor consumption and concentration hours were both higher before painful episodes with bleeding compared to the groups without bleeding, (2) factor consumption and concentration hours in episodes of patients with joint bleeds were not less than randomly…”
Background2013 revised edition : hemostatic treatment guidelines for hemophilia patients without inhibitors
(2013) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.24.619 · Cited by 17
Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B
Zhang, R., Wang, Q., Zhang, L., & Chen, S. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0390-2 · Cited by 16
[Economic impact of hemophilia type A and B in Mexico].
Carlos‐Rivera, F., Gasca-Pineda, R., Majluf‐Cruz, A., & Garcı́a-Chávez, J. (2016) · PubMed · Cited by 16
Iorio, A. (2017) · Haemophilia · doi:10.1111/hae.13176 · Cited by 16
Tiede, A., Bonanad, S., Santamaría, A., Goldmann, G., Canaro, M., Palomero, A., Frade, L. J. G., Megías‐Vericat, J. E., García, M. F. M., Candel, F. G., et al. (2020) · Haemophilia · doi:10.1111/hae.14178 · Cited by 16
“Von Willebrand disease All severities 50 67 (0-106) 6 (1-14) 0 (0-3) 94 (32-136) 104 (40-144)”
Secondary failure: immune responses to approved protein therapeutics
Lagassé, H. A. D., McCormick, Q., & Sauna, Z. E. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.08.003 · Cited by 19
Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On‐Demand
Unim, B., Veneziano, M. A., Boccia, A., Ricciardi, W., & Torre, G. L. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/596164 · Cited by 16
“According to the scientific literature, prophylaxis is the first choice therapy, especially for children with severe haemophilia A [8].”
BackgroundIntegrated postural analysis in children with haemophilia
Boccalandro, E. A., Pasta, G., Mannucci, P. M., Santagostino, E., Peyvandi, F., Seuser, A., Mancuso, M. E., & Solimeno, L. P. (2014) · Haemophilia · doi:10.1111/hae.12369 · Cited by 16
Chen, Y., Chen, L., Cheng, S., Pan, R., Chang, S., & Li, T. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.01646 · Cited by 18
Emerging drugs for the treatment of hemophilia A and B
Morfini, M., & Zanon, E. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220536 · Cited by 17
“After the pioneer observations in Sweden and the USA [9,10], two randomized controlled studies [11,12] definitely proved that prophylaxis, compared to on-demand treatment, can significantly reduce the occurrence of joint bleedings.”
BackgroundRecent advances in hemophilia B therapy
Horava, S. D., & Peppas, N. A. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0365-8 · Cited by 16
Suh, H. C., Kim, D., Kang, S. H., Seo, K. M., Kim, H. S., Lee, J. Y., Lee, S. Y., & Yoo, K. Y. (2018) · Annals of Rehabilitation Medicine · doi:10.5535/arm.2018.42.3.449 · Cited by 16
“The primary aim of care for haemarthroses in hemophilia is to prevent and treat bleeding by supplementing the deficient clotting factor [6].”
BackgroundOlivieri, M., Sommerer, P., Maro, G. S., & Yan, S. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13378 · Cited by 16
Schweiger, H. G., Rejtő, J., Hofbauer, C. J., Berg, V., Allacher, P., Zwiauer, K., Feistritzer, C., Schuster, G., Ay, C., Reipert, B. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005745 · Cited by 17
“6 ,7-9 Although prophylactic nonfactor replacement therapies have recently been approved (eg, emicizumab) or are currently in development, experience with respect to their use and associated risks is still limited.”
Langley, A. R., Stain, A. M., Chan, A. K. C., McLimont, M., Chait, S., Wu, J. K., Poon, M. ‐., Card, R., Israels, S. J., Laferriere, N., et al. (2015) · Haemophilia · doi:10.1111/hae.12713 · Cited by 16
Lambert, T., Auerswald, G., Benson, G. M., Hedner, U. K. E., Jiménez‐Yuste, V., Ljung, R. C. R., Morfini, M., Remor, E., Santagostino, E., & Šalek, S. Z. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.02.015 · Cited by 16
“In addition, MRI images frequently do not correlate with clinical status [8], and it could be suggested that MRI may therefore not be the best tool to use in the follow-up of children.”
BackgroundSharma, A., Mathew, M. E., Sriganesh, V., & Reiss, U. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010822.pub3 · Cited by 16
Evolving Complexity in Hemophilia Management
Croteau, S. E. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.01.004 · Cited by 20
Nano‐evidence for joint microbleeds in hemophilia patients
Puetz, J. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14242 · Cited by 16
Oldenburg, J., Carcao, M. D., Lentz, S. R., Mahlangu, J. N., Mancuso, M. E., Matsushita, T., Négrier, C., Clausen, W. H. O., Ehrenforth, S., & Young, G. A. (2018) · Haemophilia · doi:10.1111/hae.13608 · Cited by 16
Mondorf, W., Eichler, H., Fischer, R. J., Holstein, K., Klamroth, R., Nimtz-Talaska, A., Wermes, C., Richter, H., & Severin, K. (2019) · Hämostaseologie · doi:10.1055/s-0038-1675575 · Cited by 16
Tolend, M., Majeed, H., Soliman, M., Daruge, P., Rodrigues, M. B., Dertkigil, S. S. J., Gibikote, S., Keshava, S. N., Stimec, J., Dunn, A. L., et al. (2020) · Haemophilia · doi:10.1111/hae.14032 · Cited by 16
Spadarella, G., Minno, A. D., Brunetti‐Pierri, N., Mahlangu, J. N., & Minno, G. D. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100737 · Cited by 19
O'Donovan, M. T., Bergin, C., Quinn, E., Singleton, E., Roche, S., Benson, J., Bird, R., Byrne, M., Duggan, C., Gilmore, R., et al. (2021) · Haemophilia · doi:10.1111/hae.14307 · Cited by 17
Forum on: the role of recombinant factor VIII in children with severe haemophilia A
Franchini, M., Coppola, A., Molinari, A. C., Santoro, C., Schinco, P., Speciale, V., & Tagliaferri, A. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2008.01975.x · Cited by 16
Musculoskeletal Manifestations of Hemophilia
Rodriguez-Merchan, E. C., & la Corte-García, H. D. (2014) · Springer eBooks · doi:10.1007/978-3-319-10780-6_1 · Cited by 16
It's Time for Gene Therapy to Get Disruptive!
Wilson, J. M. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.2530 · Cited by 17
Metadata
- Authors
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G. A., Thompson, A. A., McRedmond, K., Soucie, J. M., Austin, H., & Evatt, B. L.
- Affiliations
- University of Colorado Denver (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 535-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167801052
- Cited by
- 1,950
- References
- 27
- Citations by year
- 2026: 57 · 2025: 70 · 2024: 98 · 2023: 115 · 2022: 106 · 2021: 123 · 2020: 127 · 2019: 110 · 2018: 114 · 2017: 107 · 2016: 123 · 2015: 116 · 2014: 131 · 2013: 116 · 2012: 112
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (U27/CCU812106, R00069)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hemophilia A, severe hemophilia, prophylaxis, episodic treatment, recombinant factor VIII, joint destruction, factor VIII inhibitors, joint hemorrhage, children, central venous catheter complications
- MeSH terms
- Child, Child, Preschool, Drug Administration Schedule, Factor VIII, Follow-Up Studies, Hemarthrosis, Hemophilia A, Hemorrhage, Humans, Infant, Infusions, Intravenous, Joint Diseases, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.